TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35787807

Group type: EXPERIMENTAL
Intervention: Laparoscopic guided minilaparotomy
Number of subjects: 112
Study: 35787831

Group type: EXPERIMENTAL
Intervention: edoxaban (3-month treatment)
Number of subjects: 100
Study: 35788016

Group type: EXPERIMENTAL
Intervention: BMI_GDM CatBoost model
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: ppBMI CatBoost model
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: BMI_2hour CatBoost model
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: BMI_Fasting CatBoost model
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: BMI_GDM2 CatBoost model
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Total gestational weight gain
Number of subjects: 561
Study: 35788031

Group type: EXPERIMENTAL
Intervention: Portable MRI examinations
Number of subjects: 14
Study: 35788100

Group type: EXPERIMENTAL
Intervention: Cook for Your Life website (online nutrition resource)
Number of subjects: 2665
Study: 35788116

Group type: EXPERIMENTAL
Intervention: 68Ga-grazytracer PET imaging
Number of subjects: 5
Study: 35788195

Group type: EXPERIMENTAL
Intervention: Modified FRENCH scale (combining ECG and cardiovascular risk factors)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Modified FRENCH scale (using CVRF collected by ED physicians)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Standard FRENCH scale (ECG-based)
Number of subjects: 505
Study: 35788251

Group type: EXPERIMENTAL
Intervention: Comorbidities including type 2 diabetes mellitus, alcoholic liver disease, hyperthyroidism, gastrointestinal bleeding, hepatic encephalopathy (HE), and hepatorenal syndrome.
Number of subjects: 2166

Group type: EXPERIMENTAL
Intervention: Presence of spontaneous bacterial peritonitis, pneumonia, and hepatic encephalopathy (HE).
Number of subjects: 2166

Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors for HBV-ACLF.
Number of subjects: 2166
Study: 35788366

Group type: EXPERIMENTAL
Intervention: Dimensional Anhedonia Rating Scale (DARS)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Lasso regression analysis
Number of subjects: 533

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 533
Study: 35788562

Group type: EXPERIMENTAL
Intervention: Presence of anti-IFN IgG
Number of subjects: 103
Study: 35788722

Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg once daily in 28-day cycles
Number of subjects: 21
Study: 35788749

Group type: EXPERIMENTAL
Intervention: Cervical lesion proportion (CLP) measure using a digital imaging technique
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Rubbery papule count (RPC)
Number of subjects: 70
Study: 35788913

Group type: EXPERIMENTAL
Intervention: Training intervention (face-to-face workshops or self-paced e-learning modules)
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 1484
Study: 35789068

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (most common treatment regimen, 24.8%)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Stage IIIA with curative surgery and resectable tumours
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Stage IIIB with ECOG score of 0/1, female gender, resectable tumours, adenocarcinoma, and curative surgery
Number of subjects: 231
Study: 35789124

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) measurement using LIAISON
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm including FC measurement
Number of subjects: 0
Study: 35789261

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) therapy during late pregnancy
Number of subjects: 157

Group type: COMPARATOR
Intervention: Untreated mothers
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Maternal HBV DNA titer
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Maternal genotype C
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Pre-S1 wild-type sequence
Number of subjects: 157
Study: 35789593

Group type: EXPERIMENTAL
Intervention: Dietary Antioxidants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without Type 1 Diabetes)
Number of subjects: 0
Study: 35789594

Group type: EXPERIMENTAL
Intervention: JOTROL (a highly bioavailable resveratrol preparation)
Number of subjects: 0
Study: 35790108

Group type: EXPERIMENTAL
Intervention: Recent trials (2002-2016)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Old trials (1980-2002)
Number of subjects: 114
Study: 35790143

Group type: EXPERIMENTAL
Intervention: Blinatumomab (9-28 μg/day for adults; 5-15 μg/m2/day for pediatrics)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 31
Study: 35790315

Group type: EXPERIMENTAL
Intervention: Ceralasertib (240 mg two times a day) plus durvalumab (1500 mg) every 4 weeks
Number of subjects: 31
Study: 35790332

Group type: EXPERIMENTAL
Intervention: Neotree e-health solution (android app with data visualisation)
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Neotree clinical decision support algorithms
Number of subjects: 15000
Study: 35790333

Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: Patient-centred health data aggregating platform
Number of subjects: 1550
Study: 35790334

Group type: EXPERIMENTAL
Intervention: Experience of violence when using the toilet
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Experience of violence when collecting water
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Worry about violence when using the toilet
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Worry about violence when collecting water
Number of subjects: 1798
Study: 35790423

Group type: EXPERIMENTAL
Intervention: Motor features assessment in symptomatic participants with f-FTLD
Number of subjects: 184
Study: 35790459

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35790566

Group type: EXPERIMENTAL
Intervention: Portal- and hepatic-vein embolization (PVE/HVE)
Number of subjects: 0
Study: 35790584

Group type: EXPERIMENTAL
Intervention: High-frame-rate contrast-enhanced ultrasound particle image velocimetry (HFR CEUS PIV)
Number of subjects: 21
Study: 35790651

Group type: EXPERIMENTAL
Intervention: Antifibrotic therapy (specifics not provided)
Number of subjects: 0
Study: 35790816

Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 317

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 317
Study: 35791008

Group type: EXPERIMENTAL
Intervention: Supra-marginal resection (extending 1 cm beyond the enhancing tumor)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Supra-marginal resection
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard gross total resection (GTR)
Number of subjects: 72
Study: 35791026

Group type: EXPERIMENTAL
Intervention: High-intensity technology-assisted training (4-week program, 3 to 5 days per week, at least 5 sessions of 45 minutes each)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-intensity technology-assisted training
Number of subjects: 14
Study: 35791625

Group type: EXPERIMENTAL
Intervention: semaglutide 2.4 mg single-dose pen-injector
Number of subjects: 0
Study: 35791694

Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 0
Study: 35792924

Group type: EXPERIMENTAL
Intervention: PegaGen (pegfilgrastim) administered once per cycle, with a single 6 mg dose injected in 99.17% of cycles.
Number of subjects: 654
Study: 35793677

Group type: EXPERIMENTAL
Intervention: mAbs (bamlanivimab)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 35793869

Group type: EXPERIMENTAL
Intervention: Bacterial burden in tumor cells
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bacterial burden
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Expression of oncogenic β-catenin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intratumor bacteria
Number of subjects: 12
Study: 35793925

Group type: EXPERIMENTAL
Intervention: Combination of HPV E4 and p16
Number of subjects: 500
Study: 35793990

Group type: EXPERIMENTAL
Intervention: DA-8010 5 mg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: DA-8010 2.5 mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306

Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 306
Study: 35794169

Group type: EXPERIMENTAL
Intervention: Linked-read sequencing and parental haplotype phasing for NIPD of triplet-repeat expansion diseases.
Number of subjects: 5
Study: 35794298

Group type: EXPERIMENTAL
Intervention: Pre-pandemic assessments of anxiety and depression
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pandemic-related stress
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Threat processing fMRI task pre-pandemic
Number of subjects: 81
Study: 35794314

Group type: EXPERIMENTAL
Intervention: Video calls
Number of subjects: 64

Group type: COMPARATOR
Intervention: Phone calls
Number of subjects: 64
Study: 35794343

Group type: EXPERIMENTAL
Intervention: BACE inhibitor verubecestat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline SUVr values
Number of subjects: 0
Study: 35794614

Group type: EXPERIMENTAL
Intervention: Regional anesthesia techniques (specifically double injection erector spinae plane block)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Regional anesthesia techniques
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Double injection erector spinae plane block
Number of subjects: 221
Study: 35794616

Group type: EXPERIMENTAL
Intervention: LCAR-B38M
Number of subjects: 74
Study: 35794623

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg bid in combination with pembrolizumab 200 mg Q3W
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg bid in combination with pembrolizumab 200 mg Q3W
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg bid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg bid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nintedanib and pembrolizumab therapy
Number of subjects: 13
Study: 35794669

Group type: EXPERIMENTAL
Intervention: Real-time digital alerts from wearable sensors
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard intermittent ward monitoring of vital signs by nurses
Number of subjects: 50
Study: 35794781

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) intervention
Number of subjects: 60
Study: 35794793

Group type: EXPERIMENTAL
Intervention: Presence of NTHi species
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strain apparition of NTHi
Number of subjects: 0
Study: 35794884

Group type: EXPERIMENTAL
Intervention: Robotic transabdominal pre-peritoneal hernia repairs (rTAPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Totally extra-peritoneal hernia repairs (TEP)
Number of subjects: 0
Study: 35795028

Group type: EXPERIMENTAL
Intervention: Biochemical indexes including white blood cell (WBC), uric acid (UA), direct bilirubin (DBIL), lactic dehydrogenase (LDH), fasting blood glucose (FBG), and low-density lipoprotein (LDL)
Number of subjects: 4613

Group type: EXPERIMENTAL
Intervention: Predictive model using multivariable logistic regression
Number of subjects: 4613

Group type: EXPERIMENTAL
Intervention: Conventional biochemical index
Number of subjects: 4613
Study: 35795051

Group type: EXPERIMENTAL
Intervention: Supervised circuit aerobic and resistance exercise (CARE) program
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Traditional aerobic and resistance exercise (TARE) program
Number of subjects: 276

Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: CARE, TARE, and AC groups
Number of subjects: 276
Study: 35795231

Group type: EXPERIMENTAL
Intervention: Italian version of the LARS score (tested twice)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 questionnaire
Number of subjects: 205
Study: 35795367

Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation (ASV)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control (no treatment of CSA)
Number of subjects: 312
Study: 35795492

Group type: EXPERIMENTAL
Intervention: Rodatristat ethyl 300 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rodatristat ethyl 600 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35795629

Group type: EXPERIMENTAL
Intervention: 3D Virtual Reality training for chemotherapy administration
Number of subjects: 83

Group type: COMPARATOR
Intervention: Document reading (Control)
Number of subjects: 83
Study: 35795849

Group type: EXPERIMENTAL
Intervention: Intraovarian injection of platelet-rich plasma (PRP) (1.5 ml) with an average of 12 injections per ovary.
Number of subjects: 80
Study: 35796199

Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 0

Group type: COMPARATOR
Intervention: ravulizumab
Number of subjects: 0
Study: 35796536

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccination
Number of subjects: 745
Study: 35796561

Group type: EXPERIMENTAL
Intervention: CVD risk education, coping skills training, physical activity, and stress management
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 41
Study: 35796785

Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride (10-min dosing)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m
Number of subjects: 37
Study: 35797012

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with pertuzumab (840 mg first cycle, 420 mg subsequent cycles), atezolizumab (1200 mg), docetaxel (75 mg/m2), and trastuzumab (600 mg subcutaneous) every 3 weeks for 6 cycles.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for patients with pCR: 12 cycles of atezolizumab, trastuzumab, and pertuzumab every 3 weeks after surgery.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for patients without pCR: 14 cycles of atezolizumab (1200 mg) plus trastuzumab emtansine (3.6 mg/kg) every 3 weeks.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (overall treatment)
Number of subjects: 67
Study: 35797174

Group type: EXPERIMENTAL
Intervention: Picture cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly salient targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consistent targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-salience target
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top-down guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bottom-up guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: AD patients
Number of subjects: 0
Study: 35797356

Group type: EXPERIMENTAL
Intervention: Diet alone
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Diet plus resistance exercise
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Diet plus aerobic exercise
Number of subjects: 141

Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 141
Study: 35797460

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Setmelanotide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical options
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening tests for rare genetic causes of obesity
Number of subjects: 0
Study: 35797864

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) treatment
Number of subjects: 11764
Study: 35798000

Group type: EXPERIMENTAL
Intervention: Homologous mRNA vaccine boosting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heterologous mRNA and Ad26.COV2.S vaccine boosting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Homologous Ad26.COV2.S boosting
Number of subjects: 0
Study: 35798027

Group type: EXPERIMENTAL
Intervention: Prolonged surgical mask use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35798241

Group type: EXPERIMENTAL
Intervention: SH-1028 (200 mg/d orally until disease progression or intolerable toxicity)
Number of subjects: 286
Study: 35798401

Group type: EXPERIMENTAL
Intervention: FFR derived from coronary computed tomography angiography revascularization planner (FFR)
Number of subjects: 120
Study: 35798405

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 35798468

Group type: EXPERIMENTAL
Intervention: S-1-based treatment after cardiotoxicity from capecitabine or 5-FU
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: S-1-based treatment
Number of subjects: 200
Study: 35798532

Group type: EXPERIMENTAL
Intervention: Long diagnostic delay (>1 year)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Short diagnostic delay (<1 year)
Number of subjects: 264
Study: 35798714

Group type: EXPERIMENTAL
Intervention: CD19 F-CAR-T
Number of subjects: 25
Study: 35799070

Group type: EXPERIMENTAL
Intervention: BiliSpec
Number of subjects: 375

Group type: COMPARATOR
Intervention: Transcutaneous bilirubinometer
Number of subjects: 375

Group type: COMPARATOR
Intervention: Reference standard (spectrophotometry)
Number of subjects: 375
Study: 35799116

Group type: EXPERIMENTAL
Intervention: Elevated serum thyroid-stimulation hormone (TSH) levels
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Higher TSH levels after adjusting for age and other risk factors
Number of subjects: 1862
Study: 35799290

Group type: EXPERIMENTAL
Intervention: SABA prescription (≥3 canisters)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: SABA prescription (≥10 canisters)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: SABA purchased OTC
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: SABA prescription and OTC purchase
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Asthma control status
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Severe exacerbations
Number of subjects: 301
Study: 35799302

Group type: EXPERIMENTAL
Intervention: CVC-OUT score < 6 points
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: CVC-OUT score
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Subclavian insertion site
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Overall population of 1,469 CVCs
Number of subjects: 1469
Study: 35799394

Group type: EXPERIMENTAL
Intervention: Selpercatinib (160 mg bid, orally, 28-day cycles)
Number of subjects: 48
Study: 35799579

Group type: EXPERIMENTAL
Intervention: Dietary intake of total fat
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dietary intake of saturated fatty acids
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dietary intake of carbohydrates
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dietary intake of fiber
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Micronutrient intake (vitamin A, D, folate, calcium)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vitamin D, calcium, and riboflavin intake
Number of subjects: 62
Study: 35799791

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 67
Study: 35799975

Group type: EXPERIMENTAL
Intervention: IYPB intervention (76 families)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care (36 families)
Number of subjects: 112
Study: 35800013

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided internal branch of the upper laryngeal nerve (USG-guided iSLN) block combined with general anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (general anesthesia only)
Number of subjects: 80
Study: 35800017

Group type: EXPERIMENTAL
Intervention: Integrated Social Cognitive and Behavioral Skill Therapy (ISST)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Neurocognitive Remediation Therapy (NCRT)
Number of subjects: 180
Study: 35800360

Group type: EXPERIMENTAL
Intervention: Intracoronary reteplase (9 mg or 18 mg)
Number of subjects: 306
Study: 35800668

Group type: EXPERIMENTAL
Intervention: Wearable electrocardiogram (ECG)
Number of subjects: 55
Study: 35800670

Group type: EXPERIMENTAL
Intervention: Two tablets of tramadol 37.5 mg/acetaminophen 325 mg ER FDC (DW-0920)
Number of subjects: 0

Group type: COMPARATOR
Intervention: One tablet of tramadol 75 mg/acetaminophen 650 mg
Number of subjects: 0
Study: 35801187

Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg every 2 weeks for 12 weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 14
Study: 35801558

Group type: EXPERIMENTAL
Intervention: Criterion-based, standardised, two-phase therapy protocol
Number of subjects: 8
Study: 35801588

Group type: EXPERIMENTAL
Intervention: Anti-nucleocapsid IgG level in the first week after positive RT-PCR test
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: History of lung disease
Number of subjects: 617

Group type: COMPARATOR
Intervention: COVID-19 disease severity, ethnicity, age, sex, and remdesivir use
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Time to first resolution of all symptoms
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Sustained symptom resolution
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 syndrome
Number of subjects: 617
Study: 35801762

Group type: EXPERIMENTAL
Intervention: Water-soluble contrast agent (iohexol) swallowing study (WSS)
Number of subjects: 762

Group type: COMPARATOR
Intervention: Modified barium swallowing study (MBSS)
Number of subjects: 762
Study: 35801788

Group type: EXPERIMENTAL
Intervention: Failed spinal anesthesia group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 35801795

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen at a flow rate of 2 L kg-1 min-1
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 27
Study: 35801915

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 964

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 964
Study: 35802001

Group type: EXPERIMENTAL
Intervention: Web-based therapy (mixed-method cognitive behavioral therapy)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 50
Study: 35802063

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (400 mg/100 mg) daily for 12 weeks
Number of subjects: 37
Study: 35802252

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX)
Number of subjects: 245